tbuckley/cabot-search huggingface dataset:
Prevention of Acute GvHD Following Negative Functional Selection of Allogeneic T-Cells Using Fas Ligand Exposure of the Graft: Preliminary Results for Launching a Clinical Study
Authors: Moran Meiron, Liat Pinkas, Hilit Levi, Tami Katz, Jacob M. Rowe, Eti Ganon, Tsila Zuckerman
Journal: Blood (2015)
THU0404 The Prevalence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review &amp; Meta-Analysis
Authors: M.C. Karreman, J.J. Luime, J.M. Hazes, A.E. Weel
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Inflammatory Bowel Disease (IBD) is a chronic disease that affects up to 0.5% of the population, comprising both Crohn9s Disease (CD) and ulcerative colitis (UC). Various extra-intestinal manifestations can occur, among which spondyloarthritis (SpA). SpA can manifest with both axial and peripheral manifestations, but prevalence estimates of these manifestations differ widely. <h3>Objectives</h3> To provide a pooled estimate of the prevalence of axial and peripheral manifestations of SpA in patients with IBD and to identify factors that might influence the prevalence estimates. <h3>Methods</h3> We systematically searched Embase, Pubmed, OvidSP, Scopus and Web-of-science databases from inception to May 2014. All articles addressing the prevalence of axial and/or peripheral manifestations of spondyloarthritis in adult IBD patients were included. Risk of bias was assessed using a quality assessment tool including items on selection bias, non-response bias, sample size and misclassification of SpA diagnosis. <h3>Results</h3> Out of 4846 studies, 60 studies were included. Sample size varied from 9 to 4454. Methodological quality of the included studies was moderate, with only a slight majority scoring positively on the individual items of the quality assessment tool. With regard to axial manifestations, the pooled prevalence of sacroiliitis was 0.11 (95% CI 0.08–0.014), whereas the pooled prevalence for ankylosing spondylitis was 0.03 (95% CI 0.03–0.04). For peripheral arthritis the pooled prevalence was 0.14 (95% CI 0.12–0.16). Few estimates were available for the prevalence of enthesitis (range from 0.01 to 0.54) and dactylitis (range from 0 to 0.04). For both axial and peripheral manifestations, the prevalence was higher in patients with CD than in patients with UC. Heterogeneity between studies was large, which might be explained by methodological quality as well as difference in geographic area, clinical setting and the use of criteria for case ascertainment as shown in figure 1 for the prevalence of SI and AS. <h3>Conclusions</h3> Spondyloarthritis is a common extraintestinal manifestation in IBD. Peripheral arthritis is slightly more common with a pooled prevalence of 0.14 than axial manifestations as sacroiliitis (pooled prevalence 0.11) and ankylosing spondylitis (pooled prevalence 0.03). For both axial and peripheral manifestations, the prevalence is higher in patients with CD than in patients with UC. <h3>Disclosure of Interest</h3> None declared
A Sense Oligonucleotide Specifically Reverses the Prothrombin Depletion and Anticoagulation Caused by ISIS 401025, an Antisense Oligonucleotide Targeting Prothrombin RNA in Mice.
Authors: Chenguang Zhao, Brett P. Monia, Andy Siwkowski, Sue Freier, Donna Witchell, Hong Zhang
Journal: Blood (2007)
Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengraftment After Low-Intensity Chemotherapy
Authors: Daniel H. Fowler, Miriam E. Mossoba, Bazetta Blacklock Schuver, Paula Layton, Frances T Hakim, Roger Kurlander, Juan Gea-Banacloche, Claude Sportes, Nancy M. Hardy, Steven Z. Pavletic, Seth M. Steinberg, Hanh Khuu, Marianna Sabatino, David Stroncek, Susan Leitman, Scott D Rowley, Michele L Donato, Andre Goy, Thea Friedman, Robert Korngold, Andrew L Pecora, Bruce L Levine, Carl H. June, Ronald E. Gress, Michael R. Bishop
Journal: Blood (2010)
Acceleration and Enhancement of T-Cell Recovery and Immune Competence by Flt3-Ligand (Flt3L) Following BMT with Low Numbers of Progenitor Cells in Immune Deficient Mice.
Authors: Evert-Jan Wils, Annoek E.C. Broers, Georges M.G.M. Verjans, Bert Niesters, Albert D.M.E. Osterhaus, Hergen Spits, Bob Lowenberg, Gerard Wagemaker, Erik Braakman, Jan J. Cornelissen
Journal: Blood (2004)
Application of a diathermic dilator for negotiating near-total antropyloric strictures
Authors: Pradeep Siddappa, Yalaka Reddy, Pankaj Gupta, Ajay Gulati, Vikas Gupta, Saroj Sinha, Rakesh Kochhar
Journal: Endoscopy (2016)

Three patients with caustic substance-induced near-total antropyloric obstruction with recurrent vomiting were found to have a totally blocked antropyloric region with no flow of contrast distally ([Fig. 1]). Patient characteristics, the treatment provided, and the outcome are summarized in [Table 1].
Dominant and Pharmacologically Sensitized ENU Mutagenesis Screens Uncover Novel Regulators of Hematopoiesis and Model Hematopoietic Disease.
Authors: William L. Stanford, Nicole M. Anderson, Zorana Milenkovic, Lia Zitano, Lee Adamson, Chen Wang, Myron Cybulsky, Kelly McNagny, Robert F. Paulson, Dwayne L. Barber, Mark D. Minden
Journal: Blood (2005)
Elevated ROS Levels in Response to CD20-Targeting Enhance Senescence Entry after Immunochemotherapy in Human B-Cell Lymphoma
Authors: J. Henry M. Däbritz, Yong Yu, Maja Milanovic, Jan R. Dörr, Andreas M. Kaufmann, Mathias T. Rosenfeldt, Bernd Dörken, Clemens A. Schmitt
Journal: Blood (2014)
Reduced Intensity Conditioning Unrelated Transplant Plus Cyclosporine and MMF as GVHD Prophylaxis: Results of a Prospective Study.
Authors: J.A. Perez-Simon, R. Martino, R. de la Camara, J. Perez de Oteiza, J.M. Moraleda, M. Diez-Campelo, A. Sureda, A. Alegre, J. Sierra, J.F. San Miguel
Journal: Blood (2005)
AB0233 Anterior Atlantoaxial Subluxation in Rheumatoid Arthritis: Prevalence and Predictive Factors
Authors: O. Akkar, J. Eddarami, L. Ichchou
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Cervical spine involvement is common and potentially severe in patients with Rheumatoid Arthritis (RA). The most common abnormality is anterior Atlanto Axial Subluxation (aAAS), which has been reported in 19–70% of patients. <h3>Objectives</h3> The aim of this study was to determinate the prevalence of aAAS by plain radiographs and to assess its predictive factors. <h3>Methods</h3> A cross-sectional study was carried out with RA patients diagnosed according to ACR 1987 or ACR/EULAR 2010 classification criteria. Demographic characteristics and features of disease were collected. Pain was measured using a visual analogue scale (VAS). RA activity was assessed by the Disease Activity Score (DAS 28). Functional disability was evaluated by the Health Assessment Questionnaire (HAQ). Joint destruction was assessed by the van der Heijde-modified Sharp Score. aAAS was assessed on lateral radiographs taken in flexion. The diagnosis was based on an anterior atlantodental interval (AADI) greater than 4 mm. Data analysis was carried out using the SPSS 20 Software. p&lt;0.05 was considered statistically significant. <h3>Results</h3> One hundred and sixteen patients with a mean±SD age of 49.07±13.23 years were recruited. Eighty-five per cent were female. Mean±SD duration of symptoms was 11.3±9.30 years. The diagnosis of aAAS was made in 11 (9.5%) of cases. RA patients with aAAS had longer disease duration, higher Sharp scores, and higher functional disability. On regression analysis, significant predictors of aAAS were disease duration (p=0.008), joint destruction (p=0.002), functional disability (p=0.028) and presence of coxitis (p=0.038). The multivariate analysis showed that structural damage was a predictive factor of aAAS (p=0.007 OR: 1.02, 95% CI 1.006–1.035) adjusted to functional disability and presence of coxitis. <h3>Conclusions</h3> The prevalence of aAAS was 9.5% in our RA population. Larger studies are required to identify the profile of RA patients at high risk of cervical spine involvement. <h3>Disclosure of Interest</h3> None declared
Molecular Characterization of the T(14;18)(q32;q21) Involving the IGH Locus and the MALT1 Gene in MALT Lymphomas
Authors: Eva Maria Murga Penas, Evelyne Callet-Bauchu, Nadine Albert, Sophie Gazzo, Françoise Berger, Gilles Salles, Carsten Bokemeyer, Judith Dierlamm
Journal: Blood (2008)
Tumor Localization and Quantitation of Adoptively Transfered T Lymphocytes in a Murine Model.
Authors: Marianne Hokland, Mikkel S. Petersen, Charlotte C. Fleischer, Hans Stødkilde-Jørgensen, Søren B. Hansen, Ulrik Skands, Hans J.G. Gundersen, Ralf Agger
Journal: Blood (2004)
Efficacy and Safety of Micafungin as An Empirical Antifungal Therapy for Suspected Fungal Infection in Patients with Hematological Disorders.
Authors: Minoru Yoshida, Kazuo Tamura, Masahiro Imamura, Yoshiro Niitsu, Takeshi Sasaki, Akio Urabe, Kazuma Ohyashiki, Tomoki Naoe, Akihisa Kanamaru, Mitsune Tanimoto, Tohru Masaoka
Journal: Blood (2008)
AB0960 Reliability of Ultrasound To Detect Gout Elementary Lesions
Authors: L. Ventura-Rios, C. Hernández-Díaz, C. Gόmez-Ruíz, S. Gallegos-Nava, P. Rodríguez Henríquez, J. Vázquez-Mellado
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The double contour (DC) seen by ultrasonography (US) was recently included in the classification criteria of gout, but this injury and other ones like tophi, hyperechoic aggregates Intra -articular and/or intra-tendinous, and bone erosions have not been validated. <h3>Objectives</h3> To evaluate the reliability of US to detect gout elementary lesions <h3>Methods</h3> Nine patients with Gout were included; diagnosis established by demonstration of monosodium urate crystals; patients were evaluated by 5 ultrasonographers in 2 rounds to detect tophi, hyperechoic aggregates, DC and bone erosions according to OMERACT definitions (1) in knee joint recesses and 1st metatarsophalangeal (MTP) joint, quadriceps, patellar and Achilles tendons bilaterally. Cohen9s Kappa was used to establish Intra and inter-observer variability; the Kappa values were assigned as follows: poor (below 0.2), just (0.21 to 0.40), moderate (0.41 to 0.60), good (0.61 to 0.80) and excellent (0.81 to 1). <h3>Results</h3> Patients were 48+10 years old and 10+6 years of disease evolution. The inter-observer Kappa was good for DC in the knee and 1st MTP joint (0.87, 95% CI 0577–1170, p=0.000), good for hyperechoic aggregates in parapatellar recess, quadriceps and patellar tendon (distal insertion) and 1st MTP joint (0.71, -1064 to 2834, 95%, p=0.0001), moderate to proximal insertion of patellar tendon (0.46, 95% CI NA-NA, p=0.168), excellent for tophi in all tendons and in 1st MTP joint (0.82, 95% CI 0366–1270, p=0.000) and the same for erosion in 1st MTP joint (0.83, 95% CI 0349–1000, p=.0003). The intra-observer reliability was good (K=0.80; 95% CI 0758–0852, p=0.0000) <h3>Conclusions</h3> The US is reliable for detecting gout elementary lesions in the knee and the 1st MTP joint. <h3>References</h3> Gutierrez M, et al. International Consensus for ultrasound lesions in gout: results of Delphi process and web-reliability exercise. Rheumatol 2015; online <h3>Disclosure of Interest</h3> None declared
Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia
Authors: Isabel Ben-Batalla, Robert Erdmann, Heather Jørgensen, Rebecca Mitchell, Thomas Ernst, Gunhild von Amsberg, Philippe Schafhausen, Janna L. Velthaus, Stephen Rankin, Richard E. Clark, Steffen Koschmieder, Alexander Schultze, Subir Mitra, Peter Vandenberghe, Tim H. Brümmendorf, Peter Carmeliet, Andreas Hochhaus, Klaus Pantel, Carsten Bokemeyer, G. Vignir Helgason, Tessa L. Holyoake, Sonja Loges
Journal: Clinical Cancer Research (2016)

Purpose: BCR-ABL kinase inhibitors are employed successfully for chronic myeloid leukemia (CML) treatment. However, resistant disease and persistence of BCR-ABL1-independent leukemia stem and progenitor cells (LSPC) remain clinical challenges. The receptor tyrosine kinase Axl can mediate survival and therapy resistance of different cancer cells. We investigated the therapeutic potential of Axl inhibition in CML.Experimental Design: We used primary cells from patients with CML and TKI-sensitive and -resistant BCR-ABL1+ CML cell lines and a novel ponatinib-resistant cell line KCL-22 PonR. We analyzed the effects of genetic and pharmacologic Axl blockade by the small-molecule Axl inhibitor BGB324 in vitro and in vivo In BCR-ABL1-unmutated cells, we also investigated BGB324 in combination with imatinib.Results: We demonstrate overexpression of Axl receptor tyrosine kinase in primary cells of patients with CML compared with healthy individuals and a further increase of Axl expression in BCR-ABL TKI-resistant patients. We show that Axl blockage decreased growth of BCR-ABL TKI-sensitive CML cells including CD34+ cells and exerts additive effects with imatinib via inhibition of Stat5 activation. BGB324 also inhibits BCR-ABL TKI-resistant cells, including T315I-mutated and ponatinib-resistant primary cells. BGB324 exerted therapeutic effects in BCR-ABL1 T315I-mutated and ponatinib-resistant preclinical mouse models. Notably, BGB324 does not inhibit BCR-ABL1 and consequently inhibits CML independent of BCR-ABL1 mutational status.Conclusions: Our data show that Axl inhibition has therapeutic potential in BCR-ABL TKI-sensitive as well as -resistant CML and support the need for clinical trials. Clin Cancer Res; 23(9); 2289-300. ©2016 AACR.
FRI0552 Patients with Rheumatoid Arthritis Are More Obese than The General Population Already at Disease Onset: A Collaborative Analysis from Three Large German RA Databases
Authors: K. Albrecht, A. Richter, J. Callhoff, D. Huscher, G. Schett, A. Zink
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> METARTHROS (Metabolic impact on joint and bone disease) is a nation-wide German network to investigate the interaction between inflammatory and metabolic diseases. <h3>Objectives</h3> To compare the distribution of the body mass index (BMI) in early and established rheumatoid arthritis (RA) with representative data from the general population. <h3>Methods</h3> The distribution of the BMI was determined with baseline data from the early arthritis cohort CAPEA and the biologics register RABBIT as well as with data of patients enrolled in the National database of the Collaborative Arthritis Centers in 2013. BMI categories of &lt;18.5 kg/m<sup>2</sup> (underweight), 18.5 to &lt;25 kg/m<sup>2</sup> (normal weight), 25 to &lt;30 kg/m<sup>2</sup> (overweight), and ≥30 kg/m<sup>2</sup> (obesity) were used. The results were stratified by age and sex and were compared to the German Ageing Study. The association of the BMI with sociodemographic features and markers of disease activity were analysed with non-parametric tests and linear models. <h3>Results</h3> The data of 1,207 (CAPEA), 12,230 (RABBIT) and 3,424 (National database) patients were evaluated. The mean age was 56/56/62 years, the mean disease duration 13 weeks/9.9 years/13.5 years and the mean DAS28 score 5.1/5.2/3.1 units, respectively. In all cohorts, obesity was more frequent (23.8%/23.4%/21.4%) than in the general population (18.2%), remaining in the age groups &lt;70 years, independent of disease duration and more prominent in females (Fig.1). Current smoking was inversely associated with BMI. Linear analyses revealed no significant association between BMI and DAS28. Fig.1 Distribution of the BMI in CAPEA, RABBIT and the National database <h3>Conclusions</h3> A higher prevalence of obesity, already seen at disease onset, supports a pathogenic role of obesity in the development of RA. This difference is more pronounced in females than in males. Patients in the cohorts with longer disease duration did not show a higher prevalence of obesity than those with recent onset RA, indicating that obesity may rather be a risk factor than a consequence of RA. <h3>Acknowledgement</h3> Metarthros is funded by the Federal Ministry of Education and Research (01EC1407D) <h3>Disclosure of Interest</h3> None declared
Serum Peptidome Based Multiple Myeloma Renal Impairment Biomarker Screening
Authors: Ju Bai, Aili He, Wanggang Zhang, Yun Yang, Jianli Wang, Pengyu Zhang, Yuandong Feng, Lei Zhang, Hongli Chen, Xiaman Wang, Xiaoru Lei, Ying Shen, Lingjuan Huang
Journal: Blood (2015)
THU0230 Is There A Difference in The Presentation of Male and Female Patients with Juvenile Systemic Sclerosis? Results from The Juvenile Scleroderma Inception Cohort
Authors: I. Foeldvari, J. Klotsche, O. Kasapcopur, A. Adrovic, M.T. Terreri, V. Stanevicha, M.M. Katsikas, E. Alexeeva, F. Sztajnbok, R. Cimaz, M. Kostik, W.A. Sifuentes-Giraldo, T. Lehman, D. Nemcova, M. Moll, M.J. Santos, T. Avcin, C. Battagliotti, J. Brunner, S. Nielsen, T. Kallinich, K. Minden, M. Janarthanan, L. Harel, Y. Uziel, D. Eleftheriou, K.S. Torok, N. Helmus
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Juvenile systemic sclerosis (jSSc) is an orphan autoimmune disease. Several adult publications looked at the differences between male and female patients with Systemic Sclerosis. There is rarity of data regarding this topic in pediatric jSSc. The juvenile scleroderma inception cohort (www.juvenilescleroderma.com) is a prospective standardized register for patients with jSSc. <h3>Objectives</h3> comparison of patients characteristic at the time of inclusion in the registry who are male or female. <h3>Methods</h3> Patients with jSSc were included worldwide to the juvenile scleroderma inception cohort. We compered the demographics and clinical characteristics of the male and female patients. <h3>Results</h3> Up till now 74 patients were enrolled, 54 with djSSc (76%) and 18 with ljSSc (24%). 14 (19%) of the patients were male (M) and 60 female (F) (81%). The mean disease duration at the time of inclusion was 9.3 in M and 9.2 in F patients. 74.4% of the M and 76.7% of the F had diffuse subset. The mean age of the onset of Raynaud symptomatic was 9.3 in M and 9.2 years in the F patients and the non-Raynaud symptomatic with 9.1 in M and 9.9 in F patients. At the time of the inclusion the mean modified Rodnan Skin Score was 20 in M and 15.1 in F patients. Anti-Scl 70 positivity was found in 42.9% in M and 32.1% in F patients. Anticentromere positivity occurred in 16.7% in M and 3.3% in F patients (p=0.027). Capillary changes were present in 50% of the M and 60% of F patients, but 50% in M and F had already history of ulcerations, but 28.6% in M and 15.5% in F had active ulceration. 57.1% of the M and 50% of the F patients had cardiopulmonary involvement. Six patients had pulmonary hypertension, they were all F. 75% of M and 46.7% of F patients had signs of interstitial lung disease on imaging. Renal involvement was around 7% in both sexes. 21.4% in M and 38.3% in F patients had gastrointestinal involvement. 92.9% of M and 55.9% in M patients had musculoskeletal involvement. <h3>Conclusions</h3> We present the data on the first 74 patients with jSSc included in our cohort. Patients with male sex have a more severe disease similar to adult male patients. <h3>Disclosure of Interest</h3> None declared
Vaccination with the Heptavalent Pneumococcal Conjugate Vaccine Prevenar™ Provides Early Protective Antibody Responses in Children after Allogeneic Stem Cell Transplantation.
Authors: Roland Meisel, Uta Dirksen, Ralf Schubert, Bernd Gruhn, Gabriele Strauss, Ulrich Duffner, Andreas Groll, Karin Beutel, Renate Bluetters-Sawatzki, Wolfgang Holter, Tobias Feuchtinger, Hans-Peter Gruettner, Stefan Zielen, Hans-Juergen Laws, Dagmar Dilloo
Journal: Blood (2005)
OC-039 Improving the Quality of Care and Reducing Costs of IBD Patients on Biologic Therapy Through a Multi-Disciplinary Biologics Clinic
Authors: E Eliadou, V Reid, M Kirkbride, J Brooks, F Birchall, K Kemp, S Levison
Journal: Gut (2016)

<h3>Introduction</h3> NICE IBD quality standard (QS81) and the IBD Standards aim to deliver high quality and safe clinical care to IBD patients throughout the UK that is patient-centred and evidence based. These aims are supported by the national biologic therapy audit. To improve and standardise the care of our IBD patients on biologic therapy we began a weekly multi-disciplinary (physicians, IBD nurses, and pharmacist) virtual biologics clinic (VBC). Here, the response to therapy is monitored (clinical scoring, well-being, laboratory results), the scheduling of investigations are coordinated, and the review and writing of prescriptions undertaken. <h3>Methods</h3> We prospectively collected data from our VBC for 8 consecutive weeks. Changes to therapy on clinical grounds were noted, and the financial implications of these changes calculated. Calculations for IFX savings were based on an average dose of 300 mg per patient plus infusion costs. The ordering of required investigations and the occurrence of adverse clinical events were recorded. <h3>Results</h3> In 8 weeks, 360 patient reviews were performed relating to 327 patients (IFX = 207, ADA = 79, VEDO = 41). Therapy was adjusted in 41/327 patients (12.5%). 5 stopped biologic therapy, 19 switched drug, 10 reduced and 7 increased therapy frequency. Net saving in prescribing was £10,928 at 8 weeks (&gt;£65 K/annum). The coordinated prescribing of medication and pharmacy sign off improved the delivery of therapy and patient satisfaction. 23 colonoscopies, 9 MR scans, and 45 outpatient appointments to assess response to therapy at 3 or 12 months, were scheduled from the VBC. 5 complications were highlighted (recurrent infection; 2 required surgery; cancer; severe IBD flare requiring hospitalisation). In total 118/357 (36%) patients had their care altered by VBC intervention (41 adjusted therapies, 77 scheduled monitoring and further clinical input. <h3>Conclusion</h3> The VBC provides a safe platform to initiate and monitor biologic therapies and to audit practices. The introduction of a multi-disciplinary VBC has altered the management of 118/327 patients (36%) based on clinical findings, results, and NICE guidance. Significant financial savings (£65 K per annum), the streamlining of prescribing, and superior patient monitoring have helped to improve the quality and safety of care provided. The transition to biosimilar anti-TNF therapies can also be facilitated using a VBC forum. <h3>Disclosure of Interest</h3> None Declared
A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly High Rates of Baseline Peripheral Neuropathy.
Authors: Paul Richardson, A. Chanan-Khan, R. Schlossman, N. Munshi, P. Wen, H. Briemberg, D. Kuter, A. Oaklander, S. Lonial, H. Hassoun, D. Doss, L. Lunde, S. Hayes, M. McKenney, K. Hande, L. Lai, A. Freeman, K. Dinand, C. McAlister, D. Warren, D. Collins, D. Esseltine, A. Amato, K. Anderson
Journal: Blood (2005)
In Vivo Evidence That Ibrutininb Deregulates Chemokine Receptor CXCR4 Surface Membrane Expression and Signaling, Along with Inhibiting B Cell Antigen Receptor Signaling, As Causes for Defective Homing and Impaired Retention of CLL Cells in Tissues
Authors: Shih-Shih Chen, Betty Y. Chang, Stella Chang, Timothy Tong, Yong-Rui Zou, Barbara Sherry, Joseph J. Buggy, Jan A. Burger, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2014)